ABSTRACT
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Type 1 diabetes is recognized as an autoimmune-mediated disorder with a variable prodromal phase characterized by the progressive loss of the insulin-producing beta-cells in the pancreatic islets in genetically at-risk individuals (1, 2) . Several facts support a critical role for environmental factors that trigger the development of type 1 diabetes. Leading environmental candidates include exposure to enteroviruses, early introduction of wheat, and insufficient vitamin D levels. The prevalence of type 1 diabetes increases with latitude of residence and decreased sunlight exposure, whereas exposure to UV light, known to induce vitamin D production in the skin, is associated with the lower incidence of type 1 diabetes in countries closer to the equator (3, 4) . These observations strengthen the hypothesis that an inadequate vitamin D status due to insufficient sun exposure, dietary uptake and/or abnormalities in its metabolism, may increase the risk of type 1 diabetes (5) . Vitamin D deficiency indeed increases the onset and severity of autoimmune type 1 diabetes in at risk children (6) and also in the non-obese diabetic (NOD) mouse (7, 8) . Moreover, most epidemiological data, based on dietary questionnaires, suggested that vitamin D supplementation during pregnancy, infancy or early adulthood may be associated with a reduced risk of type 1 diabetes later in life (6, 9, 10) . It has been suggested that vitamin D in early life is important for gut maturation, thereby reducing permeability for agents/proteins that can act as potent antigenic stimuli (11, 12) .
In spite of these exciting results, several areas of controversy remain in this domain and randomized, double-blinded, placebo-controlled trials with extended observation periods in humans are limited.
Moreover, most of the human studies have several shortcomings, including recall bias, absence of repeated 25(OH)D measurements, and lack of a quantifiable evaluation of intake of vitamin D from food or supplements, or data on sunlight exposure. So far, convincing evidence is missing on whether dietary vitamin D as either D 2 (ergocalciferol, from plants) or D 3 (cholecalciferol, from animals) can reduce or prevent type 1 diabetes. Moreover, it remains unclear what formulation, dose, route or duration of treatment is ideal to intervene in the diabetes process. In a small pilot study from our group, NOD mice treated with a daily dose of 1,000 international units (IU) (25 µg) of 5 cholecalciferol (given i.p. from 3 until 70 days of age) were unaffected in their diabetes presentation (13) , while the active form of vitamin D 3 , 1,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 , 5 µg/kg given i.p. on alternative days) from weaning until 200 days of age clearly reduced the development of autoimmune diabetes, although this inhibition occurred only at doses that also caused mild hypercalcemia and bone demineralization (7, 14) . In another study, oral administration of 50 ng of 1,25(OH) 2 D 3 per day reduced diabetes incidence compared to vitamin D-deficient NOD mice (8) .
In the present study, we evaluated the effects of high-dose oral vitamin D 3 At the time of the experiments, the breeding stock had a diabetes incidence of 84% in female and 38% in male mice. Animals were maintained in accordance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals.
Experimental design
NOD mice were randomly assigned to be fed either a vitamin D 3 -sufficient control diet or a vitamin D 3 -supplemented diet during three periods of life. The control diet consisted of Ssniff® R/M-H diet plus 1% calcium, 0.7% phosphorus and 1,000 IU vitamin D 3 /kg diet (4 IU a day/based on a consumption of 4 g of chow per 20 g of BW daily). The vitamin D 3 -supplemented diet consisted of Ssniff® R/M-H diet plus 1% calcium, 0.7% phosphorus and 200,000 IU vitamin D 3 /kg diet (800 IU a day) (Ssniff®, BioServices BV, Uden, The Netherlands). The different feeding periods were earlylife (age 3-14 weeks), lifelong (age 3-35 weeks), and during pregnancy and neonatal life (until the end of lactation). All mice were monitored until 35 weeks of age. The research protocol of this study was approved and performed in accordance with the Ethics Committees of the KU Leuven (Leuven, Belgium).
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Histology, immunohistochemistry and insulin determination
Severity of insulitis was assessed by histological screening of pancreatic sections of at least four animals per group imbedded in paraffin taken from experimental NOD mice at 35 weeks of age. Six µm tissue sections from formalin-fixed paraffin-embedded pancreases of each animal were cut and collected 100 µm apart, then stained with hematoxylin eosin. Islets were observed under light microscopy at 20× or 40×, enumerated and graded by an independent investigator in blinded fashion.
At least 25 islets per pancreatic sample were scored for islet infiltration as follows: 0, no infiltration; 1, peri-insulitis; 2, lymphocyte infiltration in less than 50% of the islet; 3, lymphocyte infiltration in more than 50% of the islet; or 4, completely destroyed islets.
Immunofluorescence detection of FoxP3 expressing cells was performed on 6 µm thick paraffin tissue sections. Briefly, after antigen retrieval (10 mM citrate buffer pH=6, 10 min), sections were incubated with FITC-conjugated anti-Foxp3 primary antibody (5 µg/mL, clone FJK-16a, eBioscience) in TBS/proteinase I with 5% BSA (overnight, 4°C), followed by AlexaFluor (AF) 488-conjugated rabbit anti-FITC antibody (12.5 µg/mL, Molecular Probes, Invitrogen). For signal amplification, AF488-conjugated anti-rabbit IgG was used (8 µg/mL, Molecular Probes). Next, insulin was revealed using guinea pig anti-swine Ab (0.3 mg/mL, 60 min, DakoCytomation) and AF555-conjugated goat anti-guinea pig IgG (4 µg/mL, 60 min, Molecular Probes). The other half of each pancreas was used for insulin content determination as described (17) .
Flow cytometric analysis
Single cell suspensions of spleen and pancreatic lymph nodes (PLN) were prepared from mice at 35 weeks of age. The following antibodies were used for staining: CD4 (GK1.5), CD8 (53-6.7), CD25 (PC61.5), CD11b (M1/70), CD11c (N418), I-A k (10-3.6, cross-reactive with I-A g7 of NOD mice), the programmed death 1 ligand (PD-L1, MIH5), interferon-γ (IFNγ), FoxP3 and matching isotype 9 controls (all eBioscience). Cells were analyzed in a Gallios flow cytometer with Kaluza software (Beckman Coulter).
Statistical Analysis
Graphs were plotted and statistics calculated with GraphPad Prism (La Jolla, San Diego, CA).
Differences in the incidence of diabetes were assessed using the Mantel-Cox Log-rank test. Results were expressed as mean ± the standard error of the mean (SEM) if normally distributed or as median and interquartile range if not normally distributed, and student's t-test or Mann-Whitney test were used for comparison between groups, respectively. P values less than 0.05 were considered statistically significant (ns: not significant, * P < 0.05, ** P < 0.01, *** P < 0.001).
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RESULTS
Safety of vitamin D 3 supplementation
Based on dose-titration studies (data not shown), we selected 800 IU per day (40, concentrations comparable to mice fed control diet until 35 weeks of age ( Supplementary Fig. 1 ).
Histological analysis of kidney and heart of the vitamin D 3 group revealed no calcifications in aorta and renal arteries (data not shown). To verify whether vitamin D 3 supplementation affected bone metabolism, serum osteocalcin and bone parameters were evaluated. Serum osteocalcin concentrations were not altered by lifelong vitamin D 3 supplementation (Table 1) , indicating no alterations in bone turnover. Moreover, bone dry weight and ratio of calcium/bone dry weight was similar to control in the vitamin D 3 group at the end of the observation period ( Table 1) . The bone microstructure analysis by µCT showed that dietary vitamin D 3 did not affect bone mineral density and did not impair cortical or trabecular bone architecture ( Fig. 1A and B) . The vitamin D 3 -supplemented diet did not affect any of the analyzed bone parameters (Fig. 1B) . Overall, long-term vitamin D 3 supplementation was tolerated well and we found no indications of vitamin D toxicity and adverse metabolic side-effects. (Fig. 2B ). When given during pregnancy and lactation, vitamin D 3 supplementation had no effect on diabetes development either in female or male offspring (Fig. 2C ).
Lifelong vitamin D 3 supplementation preserves beta-cell function and reduces severe insulitis
Prevention of diabetes by vitamin D 3 suggests preservation of sufficient beta-cell mass and/or function. To test this, we first did an intraperitoneal glucose tolerance test and found that the diseasefree vitamin D 3 group controlled a glucose bolus with similar efficiency as normoglycemic NOD mice on control diet (Fig. 3A) . Second, the insulin content of pancreases harvested from disease-free vitamin D 3 -supplemented mice was comparable to amounts present in normoglycemic controls.
Importantly, pancreases of disease-free vitamin D 3 -supplemented animals contained significantly more insulin than pancreases of diabetic NOD mice on control diet at 35 weeks of age (Fig. 3B ).
Third, scoring of the insulitis revealed that immune infiltration in islets worsened in the control
Page 12 of 38 Diabetes group, whereas less severe insulitis, including a higher number of insulitis free islets, were observed in the majority of vitamin D 3 -supplemented mice ( Fig. 3C and D) . Taken together, treatment efficiency was not only reflected in parameters measuring beta-cell function and mass, but also in the grade of insulitis. 
Vitamin
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DISCUSSION
Vitamin D is a pro-hormone that is well-known for its role in calcium homeostasis and bone mineralization and metabolism, but accumulating data suggest additional roles in many important body functions, including the regulation of both innate and adaptive immune responses. In humans, the daily vitamin D intake recommended by the Institute of Medicine (IOM) is 400 IU per day for children less than 1 year, up to 600 IU per day for all individuals between 1 and 70 years, assuming already some sunlight exposure, and 800 IU per day for individuals older than 70 years (21).
However, many clinicians suggest that, for a good health state and to allow extra-skeletal benefits, the daily supply of vitamin D from all sources should be greater than 800 IU.
Until now, data are very limited on whether dietary vitamin D supplements can in fact modify the course of autoimmune diseases such as type 1 diabetes in humans. These studies often lack precise information on dosage and regimen of vitamin D supplementation, which can lead to contradictory results. Meta-analysis of records from 4 case-control studies and one cohort study imply that the risk of type 1 diabetes development significantly reduced in children treated with regular vitamin D between 7 and 12 months of age compared to those who were supplemented before 7 months of age or not supplemented at all (5, 22) . A recent meta-analysis of 2 cohort studies and 6 case-control studies on vitamin D intake during early-life corroborated these findings (23). The importance of maternal vitamin D intake during pregnancy is also not clear: a case-control study in Norway indicated that the risk of type 1 diabetes was higher in the offspring of women with the lowest 25(OH)D concentrations (10) , whereas other studies did not find any correlation between maternal serum 25(OH)D values and type 1 diabetes risk in the offspring (24,25). Only properly-designed, randomized and long-term trials will bring the definitive answer.
Here, we provide the first evidence that only early and lifelong vitamin D 3 supplementation with 800 IU per day, which significantly increased serum 25(OH)D 3 levels above sufficiency and corrected the immunological defects in diabetes-prone mice that already had sufficient, even high, vitamin D 3 Summary data (mean ± SEM) from female and male (n = 4-5/experiment). NOD mice were on normal chow (4 IU vitamin D, control) or chow supplemented with 800 IU per day of vitamin D 3 .
Statistical significance was calculated by student t-test. *** P < 0.001 vs. controls. at 35 weeks of age. Statistical significance was calculated using Student t-test. ns: not significant. measurements of blood glucose levels >200 mg/dL were considered diabetic. Statistical significance was calculated versus NOD mice on control chow by Mantel-Cox log-rank test. * P <0.05, ** P <0.01, *** P < 0.001. was calculated using Mann-Whitney test; ns: not significant; * P <0.05, ** P <0.01, *** P < 0.001. 
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